Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2020

  • Life Sciences
  • 30 April 2020
  • 276 Pages
  • Formats:    
  • Report Code: 24WT-3554

Chronic Kidney Disease Pipeline Review H1 - Overview

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 11, 11, 2, 23, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
Introduction
Chronic Kidney Disease (Chronic Renal Failure) - Overview
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
Appendix
List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algernon Pharmaceuticals Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algomedix Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aronora Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cadila Healthcare Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cinkate Corp, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DJS Antibodies Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec SE, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by G3 Pharmaceuticals Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Icagen Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Indalo Therapeutics Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by INVENT Pharmaceuticals Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ITB-Med AB, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kaleido Biosciences Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KidneyCure Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kintai Therapeutics Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Liminal BioSciences Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Merck & Co Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Meridigen Biotech Co Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OrthoTrophix Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProKidney LLC, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Redx Pharma Plc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Renibus Therapeutics Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Scohia Pharma Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sentien Biotechnologies Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicocell Biomed Co Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vidasym Inc, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020 (Contd..1), H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020 (Contd..2), H1 2020

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020
CHOOSE YOUR BUYING OPTION

NEED A HELP?

Submit your research need or query below

+91 9169162030 (Asia)
help@primemarketreports.com